|
||||||
|
 | |
| |
| Differntial gene expression between RNA A-to-I edited tumor samples versus normal samples |
| |
| |
| The effects of the RNA editing to the stability of the RNA structures |
| |
| |
| |
| |
|
Editing gene: HTR2C (CAeditome ID:3358) |
Gene summary for HTR2C |
 Gene summary |
| Gene information | Gene symbol | HTR2C | Gene ID | 3358 |
| Gene name | 5-hydroxytryptamine receptor 2C | |
| Synonyms | 5-HT1C|5-HT2C|5-HTR2C|5HTR2C|HTR1C | |
| Cytomap | Xq23 | |
| Type of gene | protein-coding | |
| Description | 5-hydroxytryptamine receptor 2C5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled5-hydroxytryptamine receptor 1Cserotonin 5-HT-1C receptorserotonin 5-HT-2C receptor | |
| Modification date | 20210529 | |
| UniProtAcc | P28335 | |
| Context |
| Gene ontology of each this gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Gene | GO ID | GO term | PubMed ID |
| HTR2C | GO:0001587 | 5-hydroxytryptamine receptor 2C | 18703043 |
| HTR2C | GO:0004993 | 5-hydroxytryptamine receptor 2C | 12970106 |
| HTR2C | GO:0004993 | 5-hydroxytryptamine receptor 2C | 7582481 |
| HTR2C | GO:0051378 | 5-hydroxytryptamine receptor 2C | 12970106 |
| HTR2C | GO:0051378 | 5-hydroxytryptamine receptor 2C | 15831837 |
| HTR2C | GO:0051378 | 5-hydroxytryptamine receptor 2C | 18703043 |
| HTR2C | GO:0051378 | 5-hydroxytryptamine receptor 2C | 19057895 |
| HTR2C | GO:0051378 | 5-hydroxytryptamine receptor 2C | 7582481 |
| HTR2C | GO:0071886 | 5-hydroxytryptamine receptor 2C | 19057895 |
| HTR2C | GO:0006874 | 5-hydroxytryptamine receptor 2C | 19057895 |
| HTR2C | GO:0007208 | 5-hydroxytryptamine receptor 2C | 12970106 |
| HTR2C | GO:0010513 | 5-hydroxytryptamine receptor 2C | 19057895 |
| HTR2C | GO:0019934 | 5-hydroxytryptamine receptor 2C | 12970106 |
| HTR2C | GO:0070374 | 5-hydroxytryptamine receptor 2C | 19057895 |
| HTR2C | GO:0098664 | 5-hydroxytryptamine receptor 2C | 18703043 |
| HTR2C | GO:0005886 | 5-hydroxytryptamine receptor 2C | 12970106 |
| HTR2C | GO:0005886 | 5-hydroxytryptamine receptor 2C | 18703043 |
| HTR2C | GO:0098666 | 5-hydroxytryptamine receptor 2C | 12970106 |
| HTR2C | GO:0098666 | 5-hydroxytryptamine receptor 2C | 18703043 |
Top |
RNA A-to-I events for HTR2C |
| RNA A-to-I editing events across TCGA 33 cancers data sets based on Ensembl gene isoform structure. |
 |
| RNA editing frequencies across 33 cancers of gene: ENSG00000147246.8 |
| RNA A-to-I editing events in Cancer. |
| CAediting_1519009(114584359, +), CAediting_1519010(114848119, +), CAediting_1519011(114848121, +), CAediting_1519012(114848125, +), CAediting_1519013(114848126, +), |
Top |
RNA editing positional annotations for HTR2C using Annovar |
| Protein coding RNA editing(s). |
| CAeditome ID | Position | Variant type | ENST | NTchange | AAchange | SIFT_score | Polyphen2_HVAR_score | PROVEAN_pred |
| CAediting_1519011 | chrX_114848121_+ | nonsynonymous SNV | ENST00000276198.4 | c.A468G | p.I156M | D | . | N |
| CAediting_1519011 | chrX_114848121_+ | nonsynonymous SNV | ENST00000371951.4 | c.A468G | p.I156M | D | . | N |
| CAediting_1519012 | chrX_114848125_+ | nonsynonymous SNV | ENST00000276198.4 | c.A472G | p.N158D | D | . | D |
| CAediting_1519012 | chrX_114848125_+ | nonsynonymous SNV | ENST00000371951.4 | c.A472G | p.N158D | D | . | D |
| CAediting_1519013 | chrX_114848126_+ | nonsynonymous SNV | ENST00000276198.4 | c.A473G | p.N158S | T | . | D |
| CAediting_1519013 | chrX_114848126_+ | nonsynonymous SNV | ENST00000371951.4 | c.A473G | p.N158S | T | . | D |
| Gene structure information of RNA editing(s). |
| CAeditome ID | Position | Variant type |
| CAediting_1519009 | chrX_114584359_+ | UTR5 |
| CAediting_1519010 | chrX_114848119_+ | exonic |
| CAediting_1519011 | chrX_114848121_+ | exonic |
| CAediting_1519012 | chrX_114848125_+ | exonic |
| CAediting_1519013 | chrX_114848126_+ | exonic |
| Repat-regional RNA editing(s). |
| CAeditome ID | Position | Repeat family | Repeat sub family | Repeat name |
Top |
RNA A-to-I editing events in the alternative splicing sites for HTR2C |
| RNA A-to-I editing(s) in the alternative splicing sites. |
| AStype | CAeditomID | Editing position | AS position | AS direction | Exonic location | Wildtype sequence | Wildtype splicing strength | RNA edited sequence | RNA edited splicing strength |
| Differential percent of spliced in (PSI) between RNA A-to-I edited and non-edited samples for ENSG00000147246.8.HTR2C. |
| Correlation between RNA A-to-I editing and PSI for ENSG00000147246.8.HTR2C. |
Top |
Differntial gene expression between RNA A-to-I edited versus non-edited samples for HTR2C |
| Differential gene expressions between RNA A-to-I edited and non-edited tumor samples. * The grey color means N/A. |
| Correlation between RNA A-to-I editing and gene expression. |
| - Differentially expressed gene between RNA A-to-I edited samples versus non-edited samples. * Click on the image to enlarge it in a new window. |
Top |
Protein coding region RNA A-to-I editings for HTR2C |
| - Lollipop plot for RNA A-to-I editings across protein structure. * Click on the image to enlarge it in a new window. |
Top |
The effects of the RNA editing to the miRNA binding sites for HTR2C |
| **If you are searching a miRNA gene with RNA editing events in its seed regions, please see the search pages of miRNA targets to discover the effects of this RNA editing event to miRNA regulations. For more information, please check the files in the Download page. |
| RNA A-to-I editing in the 3'-UTR regions of mRNA gained miRNA binding sites. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in the 3'-UTR regions of mRNA lost miRNA binding sites. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in lncRNA gained miRNA binding sites. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in lncRNA lost miRNA binding sites. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in miRNAs gained binding to lncRNA. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in miRNAs lost binding to lncRNA. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in miRNAs gained binding to the 3'-UTR region of mRNA. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| CAediting_688081 | chr9_63819627_+ | ENSG00000147246.8 | ENST00000371951 | hsa-miR-4477b | 114908031 | 114908038 | 8mer-1a | 114908020 | 114908038 | 152 | -15.47 |
| CAediting_688080 | chr9_63819626_+ | ENSG00000147246.8 | ENST00000371950 | hsa-miR-4477b | 114909688 | 114909694 | 7mer-m8 | 114909672 | 114909695 | 155 | -10.23 |
| CAediting_688081 | chr9_63819627_+ | ENSG00000147246.8 | ENST00000371950 | hsa-miR-4477b | 114908031 | 114908038 | 8mer-1a | 114908020 | 114908038 | 152 | -15.47 |
| CAediting_688080 | chr9_63819626_+ | ENSG00000147246.8 | ENST00000276198 | hsa-miR-4477b | 114909688 | 114909694 | 7mer-m8 | 114909672 | 114909695 | 155 | -10.23 |
| CAediting_688081 | chr9_63819627_+ | ENSG00000147246.8 | ENST00000276198 | hsa-miR-4477b | 114908031 | 114908038 | 8mer-1a | 114908020 | 114908038 | 152 | -15.47 |
| CAediting_1229414 | chr17_67471546_+ | ENSG00000147246.8 | ENST00000371951 | hsa-miR-548aa | 114907488 | 114907495 | 8mer-1a | 114907469 | 114907495 | 143 | -9.1 |
| CAediting_524911 | chr7_5495852_- | ENSG00000147246.8 | ENST00000371951 | hsa-miR-589-3p | 114907875 | 114907881 | 7mer-m8 | 114907857 | 114907882 | 147 | -13.45 |
| CAediting_1229414 | chr17_67471546_+ | ENSG00000147246.8 | ENST00000371950 | hsa-miR-548aa | 114907488 | 114907495 | 8mer-1a | 114907469 | 114907495 | 143 | -9.1 |
| CAediting_77128 | chr1_85133844_+ | ENSG00000147246.8 | ENST00000371950 | hsa-miR-4423-3p | 114907009 | 114907015 | 7mer-m8 | 114906992 | 114907016 | 153 | -23.1 |
| CAediting_77128 | chr1_85133844_+ | ENSG00000147246.8 | ENST00000371950 | hsa-miR-4423-3p | 114908890 | 114908896 | 7mer-m8 | 114908877 | 114908897 | 140 | -13.95 |
| CAediting_228905 | chr2_188297554_+ | ENSG00000147246.8 | ENST00000371950 | hsa-miR-561-3p | 114908604 | 114908610 | 7mer-m8 | 114908589 | 114908611 | 155 | -11.91 |
| CAediting_396018 | chr5_1062918_- | ENSG00000147246.8 | ENST00000371950 | hsa-miR-4635 | 114909689 | 114909695 | 7mer-m8 | 114909675 | 114909696 | 149 | -15.1 |
| CAediting_442554 | chr5_154685830_+ | ENSG00000147246.8 | ENST00000371950 | hsa-miR-1303 | 114907173 | 114907179 | 7mer-m8 | 114907160 | 114907180 | 147 | -14 |
| CAediting_524911 | chr7_5495852_- | ENSG00000147246.8 | ENST00000371950 | hsa-miR-589-3p | 114907875 | 114907881 | 7mer-m8 | 114907857 | 114907882 | 147 | -13.45 |
| CAediting_1229414 | chr17_67471546_+ | ENSG00000147246.8 | ENST00000276198 | hsa-miR-548aa | 114907488 | 114907495 | 8mer-1a | 114907469 | 114907495 | 143 | -9.1 |
| CAediting_77128 | chr1_85133844_+ | ENSG00000147246.8 | ENST00000276198 | hsa-miR-4423-3p | 114908890 | 114908896 | 7mer-m8 | 114908877 | 114908897 | 140 | -13.95 |
| CAediting_228905 | chr2_188297554_+ | ENSG00000147246.8 | ENST00000276198 | hsa-miR-561-3p | 114908604 | 114908610 | 7mer-m8 | 114908589 | 114908611 | 155 | -11.91 |
| CAediting_396018 | chr5_1062918_- | ENSG00000147246.8 | ENST00000276198 | hsa-miR-4635 | 114909689 | 114909695 | 7mer-m8 | 114909675 | 114909696 | 149 | -15.1 |
| CAediting_524911 | chr7_5495852_- | ENSG00000147246.8 | ENST00000276198 | hsa-miR-589-3p | 114907875 | 114907881 | 7mer-m8 | 114907857 | 114907882 | 147 | -13.45 |
| RNA A-to-I editing in miRNAs lost binding to the 3'-UTR mRNA. |
| CAeditom_ID | Position | ENSG | ENST | miRNA | Targetscan start | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| CAediting_1160181 | chr17_7017644_- | ENSG00000147246.8 | ENST00000371951 | hsa-miR-195-3p | 114907505 | 114907511 | 7mer-m8 | 114907491 | 114907512 | 145 | -4.88 |
| CAediting_228905 | chr2_188297554_+ | ENSG00000147246.8 | ENST00000371951 | hsa-miR-561-3p | 114908442 | 114908448 | 7mer-m8 | 114908429 | 114908449 | 141 | -10.44 |
| CAediting_573001 | chr7_92204086_- | ENSG00000147246.8 | ENST00000371950 | hsa-miR-1285-5p | 114907577 | 114907583 | 7mer-m8 | 114907563 | 114907584 | 152 | -16.49 |
| CAediting_442554 | chr5_154685830_+ | ENSG00000147246.8 | ENST00000371950 | hsa-miR-1303 | 114908759 | 114908765 | 7mer-m8 | 114908743 | 114908766 | 149 | -19 |
| CAediting_1160181 | chr17_7017644_- | ENSG00000147246.8 | ENST00000371950 | hsa-miR-195-3p | 114907505 | 114907511 | 7mer-m8 | 114907491 | 114907512 | 145 | -4.88 |
| CAediting_393 | chr1_1167164_+ | ENSG00000147246.8 | ENST00000371950 | hsa-miR-200b-3p | 114908876 | 114908882 | 7mer-m8 | 114908860 | 114908883 | 151 | -10.92 |
| CAediting_688080 | chr9_63819626_+ | ENSG00000147246.8 | ENST00000371950 | hsa-miR-4477b | 114909447 | 114909454 | 8mer-1a | 114909431 | 114909454 | 146 | -12.89 |
| CAediting_688081 | chr9_63819627_+ | ENSG00000147246.8 | ENST00000371950 | hsa-miR-4477b | 114909447 | 114909454 | 8mer-1a | 114909431 | 114909454 | 146 | -12.89 |
| CAediting_228905 | chr2_188297554_+ | ENSG00000147246.8 | ENST00000371950 | hsa-miR-561-3p | 114908442 | 114908448 | 7mer-m8 | 114908429 | 114908449 | 141 | -10.44 |
| CAediting_228905 | chr2_188297554_+ | ENSG00000147246.8 | ENST00000371950 | hsa-miR-561-3p | 114909785 | 114909791 | 7mer-m8 | 114909766 | 114909792 | 154 | -11.55 |
| CAediting_980496 | chr14_31014685_- | ENSG00000147246.8 | ENST00000371950 | hsa-miR-624-3p | 114907547 | 114907554 | 8mer-1a | 114907534 | 114907554 | 142 | -9.54 |
| CAediting_573001 | chr7_92204086_- | ENSG00000147246.8 | ENST00000276198 | hsa-miR-1285-5p | 114907577 | 114907583 | 7mer-m8 | 114907563 | 114907584 | 152 | -16.49 |
| CAediting_1160181 | chr17_7017644_- | ENSG00000147246.8 | ENST00000276198 | hsa-miR-195-3p | 114907505 | 114907511 | 7mer-m8 | 114907491 | 114907512 | 145 | -4.88 |
| CAediting_393 | chr1_1167164_+ | ENSG00000147246.8 | ENST00000276198 | hsa-miR-200b-3p | 114908876 | 114908882 | 7mer-m8 | 114908860 | 114908883 | 151 | -10.92 |
| CAediting_688080 | chr9_63819626_+ | ENSG00000147246.8 | ENST00000276198 | hsa-miR-4477b | 114909447 | 114909454 | 8mer-1a | 114909431 | 114909454 | 146 | -12.89 |
| CAediting_688081 | chr9_63819627_+ | ENSG00000147246.8 | ENST00000276198 | hsa-miR-4477b | 114909447 | 114909454 | 8mer-1a | 114909431 | 114909454 | 146 | -12.89 |
| CAediting_228905 | chr2_188297554_+ | ENSG00000147246.8 | ENST00000276198 | hsa-miR-561-3p | 114908442 | 114908448 | 7mer-m8 | 114908429 | 114908449 | 141 | -10.44 |
| CAediting_228905 | chr2_188297554_+ | ENSG00000147246.8 | ENST00000276198 | hsa-miR-561-3p | 114909785 | 114909791 | 7mer-m8 | 114909766 | 114909792 | 154 | -11.55 |
| Differentially expressed gene-miRNA network |
Top |
The effects of the RNA editing to the stability of the RNA structures for HTR2C |
| - RNA A-to-I editing in mRNA. * Click on the image to enlarge it in a new window. |
| ENST | ENST type | RNA structure without RNA A-to-I editing. | RNA structure with RNA A-to-I editing. |
| RNA A-to-I editing in RNA structures for Minimum free energy (MFE). |
| CAeditom_ID | ENST | Editing_Position | MFE_withoneAI | MFE_withoutAI | MFE_withmultipleAI |
Top |
Relation with ADAR for HTR2C |
| Correlation between ADAR gene expression and RNA editing frequency |
| Cancer | CAeditomID | position | ADAR1 (p-val) | ADAR1 (coeff.) | ADAR2 (p-val) | ADAR2 (coeff.) | ADAR3 (p-val) | ADAR3 (coeff.) |
Top |
Relation with cancer stages for HTR2C |
| Correlation between Cancer stages and RNA editing frequency |
| Cancer | Stage_type | CAeditomID | position | P-val | Coeff. |
Top |
Relation with survival for HTR2C |
| Correlation between RNA editing and survival |
| Cancer | CAeditomID | position | KMpvalue | Coxpvalue | CoxHR |
Top |
RelatedDrugs for HTR2C |
| Approved drugs targeting this gene. (DrugBank Version 5.1.8 2021-01-03) |
| Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| HTR2C | P28335 | DB00246 | Ziprasidone | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB00247 | Methysergide | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB00248 | Cabergoline | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB00321 | Amitriptyline | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB00363 | Clozapine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB00370 | Mirtazapine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB00408 | Loxapine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB00434 | Cyproheptadine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB00458 | Imipramine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB00502 | Haloperidol | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB00540 | Nortriptyline | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB00543 | Amoxapine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB00623 | Fluphenazine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB00696 | Ergotamine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB00726 | Trimipramine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB00777 | Propiomazine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB00805 | Minaprine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB00924 | Cyclobenzaprine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB01049 | Ergoloid mesylate | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB01175 | Escitalopram | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB01224 | Quetiapine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB01267 | Paliperidone | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB04871 | Lorcaserin | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB06153 | Pizotifen | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB06216 | Asenapine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB09195 | Lorpiprazole | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB11273 | Dihydroergocornine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved |
| HTR2C | P28335 | DB13345 | Dihydroergocristine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|experimental |
| HTR2C | P28335 | DB01239 | Chlorprothixene | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|experimental|investigational|withdrawn |
| HTR2C | P28335 | DB00574 | Fenfluramine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|illicit|investigational|withdrawn |
| HTR2C | P28335 | DB01191 | Dexfenfluramine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|illicit|investigational|withdrawn |
| HTR2C | P28335 | DB00193 | Tramadol | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational |
| HTR2C | P28335 | DB00334 | Olanzapine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational |
| HTR2C | P28335 | DB00589 | Lisuride | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational |
| HTR2C | P28335 | DB00656 | Trazodone | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational |
| HTR2C | P28335 | DB00714 | Apomorphine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational |
| HTR2C | P28335 | DB00715 | Paroxetine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational |
| HTR2C | P28335 | DB00734 | Risperidone | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational |
| HTR2C | P28335 | DB00934 | Maprotiline | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational |
| HTR2C | P28335 | DB01142 | Doxepin | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational |
| HTR2C | P28335 | DB01151 | Desipramine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational |
| HTR2C | P28335 | DB01200 | Bromocriptine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational |
| HTR2C | P28335 | DB01238 | Aripiprazole | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational |
| HTR2C | P28335 | DB01403 | Methotrimeprazine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational |
| HTR2C | P28335 | DB04948 | Lofexidine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational |
| HTR2C | P28335 | DB06148 | Mianserin | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational |
| HTR2C | P28335 | DB06594 | Agomelatine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational |
| HTR2C | P28335 | DB12141 | Gilteritinib | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational |
| HTR2C | P28335 | DB14185 | Aripiprazole lauroxil | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational |
| HTR2C | P28335 | DB00477 | Chlorpromazine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational|vet_approved |
| HTR2C | P28335 | DB01242 | Clomipramine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational|vet_approved |
| HTR2C | P28335 | DB01392 | Yohimbine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational|vet_approved |
| HTR2C | P28335 | DB01186 | Pergolide | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational|vet_approved|withdrawn |
| HTR2C | P28335 | DB01079 | Tegaserod | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational|withdrawn |
| HTR2C | P28335 | DB06144 | Sertindole | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|investigational|withdrawn |
| HTR2C | P28335 | DB00420 | Promazine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|vet_approved |
| HTR2C | P28335 | DB00472 | Fluoxetine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|vet_approved |
| HTR2C | P28335 | DB01221 | Ketamine | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|vet_approved |
| HTR2C | P28335 | DB01149 | Nefazodone | 5-hydroxytryptamine receptor 2C | SmallMoleculeDrug | approved|withdrawn |
Top |
RelatedDiseases for HTR2C |
| Diseases associated with this gene. (DisGeNet 7.0) |
| Gene | Disease ID | Disease name | # pubmeds | Source |
| HTR2C | C0001973 | Alcoholic Intoxication, Chronic | 5 | PSYGENET |
| HTR2C | C0005586 | Bipolar Disorder | 5 | PSYGENET |
| HTR2C | C0011570 | Mental Depression | 5 | PSYGENET |
| HTR2C | C0011581 | Depressive disorder | 5 | PSYGENET |
| HTR2C | C0041696 | Unipolar Depression | 5 | PSYGENET |
| HTR2C | C0525045 | Mood Disorders | 5 | PSYGENET |
| HTR2C | C1269683 | Major Depressive Disorder | 5 | PSYGENET |
| HTR2C | C0036341 | Schizophrenia | 4 | PSYGENET |
| HTR2C | C0524620 | Metabolic Syndrome X | 3 | CTD_human |
| HTR2C | C0028754 | Obesity | 2 | CTD_human |
| HTR2C | C0043094 | Weight Gain | 2 | CTD_human |
| HTR2C | C0085159 | Seasonal Affective Disorder | 2 | PSYGENET |
| HTR2C | C0009171 | Cocaine Abuse | 1 | PSYGENET |
| HTR2C | C0027796 | Neuralgia | 1 | CTD_human |
| HTR2C | C0038587 | Substance Withdrawal Syndrome | 1 | CTD_human |
| HTR2C | C0038870 | Neuralgia, Supraorbital | 1 | CTD_human |
| HTR2C | C0042656 | Neuralgia, Vidian | 1 | CTD_human |
| HTR2C | C0086189 | Drug Withdrawal Symptoms | 1 | CTD_human |
| HTR2C | C0087169 | Withdrawal Symptoms | 1 | CTD_human |
| HTR2C | C0234247 | Neuralgia, Atypical | 1 | CTD_human |
| HTR2C | C0234249 | Neuralgia, Stump | 1 | CTD_human |
| HTR2C | C0423711 | Neuralgia, Perineal | 1 | CTD_human |
| HTR2C | C0423712 | Neuralgia, Iliohypogastric Nerve | 1 | CTD_human |
| HTR2C | C0751217 | Hyperkinesia, Generalized | 1 | CTD_human |
| HTR2C | C0751371 | Neuralgia, Ilioinguinal | 1 | CTD_human |
| HTR2C | C0751372 | Nerve Pain | 1 | CTD_human |
| HTR2C | C0751373 | Paroxysmal Nerve Pain | 1 | CTD_human |
| HTR2C | C3887506 | Hyperkinesia | 1 | CTD_human |
